Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyra Therapeutics, Inc. filings document the company's transition from a Nasdaq-listed clinical-stage biotechnology issuer toward delisting, deregistration and wind-down disclosures. Form 25 and Form 15 filings address removal of Lyra common stock from Nasdaq listing and registration, along with termination or suspension of Exchange Act reporting obligations for the covered security.
Lyra's recent Form 8-K reports cover exit and disposal activities, suspension of further LYR-210 development, workforce and executive-employment changes, lease and sublease terminations, payment obligations, notices of default, continued-listing matters, and related capital-structure and governance disclosures.
Lyra Therapeutics director W. Bradford Smith reported a disposition of common stock back to the company. On this Form 4, he returned 640 shares to the issuer in a transaction coded as a disposition to issuer at a reported price of $0.00 per share, leaving him with no directly held shares afterward.
Lyra Therapeutics filed a Form 25 notifying removal of its Common Stock from The Nasdaq Capital Market. The company submitted the notification on April 20, 2026. The filing covers Common Stock, par value $0.001 per share, and is submitted under Section 12(b) of the Exchange Act.
Lyra Therapeutics, Inc. has terminated its sublease for approximately 23,704 rentable square feet at 880 Winter Street in Waltham, Massachusetts. The sublease, originally dated December 21, 2023, terminated effective March 31, 2026, with the premises to be surrendered no later than May 31, 2026.
As part of the termination, Lyra agreed to pay a termination payment of $2,100,000.00. After Lyra completes its surrender obligations and this payment is made, RVAC Medicines (US), Inc. will release and return Lyra’s $600,501.32 letter of credit security deposit. The company’s rent obligations under the sublease ended on January 31, 2026.
Lyra Therapeutics is exiting two Massachusetts office leases earlier than planned in exchange for cash payments and forfeited deposits. The company agreed with ARE-480 Arsenal Street, LLC to end its 480 Arsenal Way lease for approximately 22,343 rentable square feet no later than May 31, 2026, instead of April 30, 2027. Lyra will forfeit a $302,514.84 letter of credit security deposit, pay a $1,000,000.00 lease modification amount, and potentially pay up to $1,500,000.00 more if a defined sale transaction closes. Rent obligations for this site ended as of January 31, 2026.
For its 880 Winter Street, Waltham lease covering approximately 28,858 rentable square feet, Lyra entered a termination agreement with BXP Waltham Woods LLC to end the lease on May 31, 2026 instead of June 30, 2033. The company will forfeit a $1,089,389.00 letter of credit security deposit and pay a $1,500,000.00 termination fee as liquidated damages, with rent obligations ending March 31, 2026. The agreement includes mutual releases effective at termination.
Lyra Therapeutics director and Principal Executive Officer Maria Palasis reported returning 2,000 shares of Common Stock to the company in a disposition to the issuer at $0.00 per share. After this transaction, she directly owns 1,094,733 shares, indicating only a small portion of her holdings was affected.
Lyra Therapeutics Principal Financial Officer Jason Cavalier returned 667 shares of Common Stock to the company. The disposition to the issuer carried a reported price of $0.00 per share. After this transaction, he directly owns 517,880 shares, indicating this was a small, routine adjustment to his holdings.
Lyra Therapeutics reports in its annual filing that it has suspended further development of LYR-210, its lead chronic rhinosinusitis treatment, and implemented deep cost reductions, including layoffs affecting substantially all remaining employees. The company is pursuing strategic alternatives such as a merger, sale, or asset transactions but notes there is no assurance any deal will occur or be attractive.
Lyra highlights serious financial strain, with operating losses of approximately $31.0 million in 2025 and $96.3 million in 2024 and acknowledges substantial doubt about its ability to continue as a going concern. It is attempting to sublease or assign costly leases, while facing delisting from the Nasdaq Capital Market and potential classification as a public shell company, which could severely limit liquidity, capital-raising options, and use of Rule 144 and Form S‑3. The company has positive Phase 3 ENLIGHTEN 2 data for LYR-210 and an extensive patent estate potentially extending to 2042, but any renewed development would require significant new funding or a strategic transaction.